Some providers do prescribe shortened intervals for specific clinical scenarios, but this should be a medical decision, not a personal one
[C]osts will continue to rise as the market matures. Just in the last year, Medicaid spending on GLP-1 drugs for the treatment of obesity increased 172% even though Medicaid only covers these drugs for obesity in 15 states
Details and Features: Concentration and Formulation: Each mL of solution contains 1000 mcg of Cyanocobalamin, providing a high-strength treatment option
Major cardiovascular outcome trials include: LEADER trial (liraglutide): Demonstrated a significant reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and high cardiovascular risk SUSTAIN-6 (semaglutide): Showed reduced cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke REWIND (dulaglutide): Confirmed cardiovascular benefits across a broad patient population SELECT trial (semaglutide): Showed reduced MACE in people with obesity without diabetes, though this evidence is not yet fully incorporated into UK labelling [17] These trials consistently found that the modest heart rate increases observed did not translate into adverse cardiovascular outcomes
If you want a deeper explanation of the mechanism, this nausea guide is a helpful companion
